Market capitalization | $6.86b |
Enterprise Value | $6.75b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 8.30 |
P/S ratio (TTM) P/S ratio | 8.42 |
P/B ratio (TTM) P/B ratio | 25.97 |
Revenue growth (TTM) Revenue growth | 29.06% |
Revenue (TTM) Revenue | $813.95m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
27 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:
27 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 814 814 |
29%
29%
|
|
Gross Profit | 780 780 |
30%
30%
|
|
EBITDA | -342 -342 |
24%
24%
|
EBIT (Operating Income) EBIT | -365 -365 |
23%
23%
|
Net Profit | -365 -365 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
Head office | United States |
CEO | Brett Monia |
Employees | 927 |
Founded | 1989 |
Website | www.ionis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.